Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Access to medicines and treatment news

Show

From To
MSF urges BMS to make daclatasvir accessible in low-and middle-income countries

Welcoming the EMA's approval of daclatasvir on August 27, 2014, the MSF said that the BMS must rapidly register daclatasvir in those countries with a high burden of hepatitis C, especially in those countries with a high prevalence of genotype 3. It also urged BMS to ensure daclatasvir is affordable in those countries with a high burden of hepatitis C.

Published
5 hours ago
From
Pharmabiz
Stock-out hits HIV treatment across India

Treatment for HIV patients across India has taken a hit, especially in Delhi and Mumbai, due to severe stock-outs of life-saving medicines reported at government-owned centres.

Published
26 August 2014
From
Times of India
The Risky Business of Limiting Medicaid Access to Sovaldi

Partially because of its high cost, nearly half the states are restricting Medicaid patients' access to an effective new hepatitis C drug. Experts say there’s no question lawsuits will come.

Published
21 August 2014
From
Governing
Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices

Share Tools Comment Print Contact Author Reprint Indian drugmakers have a shot at bringing Gilead Sciences' ($GILD) hot new hepatitis C drug to their country. The California-based company is in talks with "a handful" of Indian pharmas to take Sovaldi (sofosbuvir) to that country and other developing nations at a fraction of the U.S. price.

Published
11 August 2014
From
Fierce Pharma
MSF: Untangling the web of antiretroviral price reductions, 17th Edition

This 17th edition of Untangling the Web of Antiretroviral Price Reductions is a departure from recent previous years. The information is presented in a new, shorter format focusing on a few key drugs as well as future regimens, along with an analysis of the current opportunities, challenges and threats faced in keeping the price of ARVs down.

Published
08 August 2014
From
MSF
Even With Obamacare, HIV Patients Are Shouldering A Huge Portion Of Their Treatment Costs

While the Affordable Care Act (ACA) forbids insurance companies from refusing coverage to people with preexisting conditions, many providers have categorized special drugs — including those that treat HIV — so that patients shoulder as much as 50 percent of the total cost.

Published
08 August 2014
From
ThinkProgress
Heightened HIV risk for people with disabilities

Inaccessible health services for people with disabilities (PWD), combined with social stigma and violence, contribute to high HIV risk - a gap that must be filled if the disabled are not to remain disproportionately vulnerable to HIV/AIDS, say health experts and activists.

Published
31 July 2014
From
IRIN Plus News
Call to EU Ministers of health and CEOs of Abbvie, BMS, Gilead, Janssen and Merck/MSD regarding universal access to curative hepatitis C treatment in the EU and beyond

Together with many large NGOs EATG has signed up to a Joint Declaration urging EU Ministries of health to consider compulsory licensing as a last resort to ensure access to the HCV direct-acting antivirals.

Published
30 July 2014
From
EATG
Of guidelines, targets and resources: the documents that defined the 2014 International AIDS Conference

If there was a phrase that defined the 20th International AIDS Conference (AIDS 2014), one that surfaced in every few presentations and kept turning up in documents,

Published
26 July 2014
By
Gus Cairns
ART demand up to 16.8 million by 2016

The projected demand for antiretroviral therapy (ART) will increase to 16.8 million person-years by the end of 2016 in low- and middle-income countries, including 15.7 million person-years of

Published
24 July 2014
By
Lesley Odendal
← First12345...77Next →

Filter by country